AusBiotech Board
The Board of Directors are elected as representatives of AusBiotech to provide strategic guidance and corporate management-related policies. The AusBiotech Board is comprised of nine members, including the Chair and the CEO.
Each Board member brings extensive experience of working in the Australian biotechnology industry, representing technical, commercial and policy expertise.
Board members
- Dr James Campbell, Chair, Prescient Therapeutics Ltd; Chair, AusBiotech
- Erica Bremner Kneipp, Research Director for the Human Health program, CSIRO; Deputy Chair, AusBiotech
- Dr Megan Baldwin, Non-Executive Director, Race Oncology
Dr Dean Moss, CEO, UniQuest Pty Ltd
Dr Marthe D’Ombrain, Head of Global Research Innovation, CSL Limited
- Professor John Skerritt AM, Enterprise Professor in Health Research Impact, University of Melbourne
- Dr Liz Dallimore, CEO & Managing Director, Argenica Therapeutics Ltd
- Dr Dell Kingsford Smith, VP, Medical Affairs, Market Access & Government Affairs, Cochlear
- Rebekah Cassidy, CEO & Managing Director, AusBiotech
